Clinical trials: Rett Syndrome

RETT Syndrome With Proven MECP2 Mutation

Repurposing Mirtazapine in Rett Syndrome

• Recruiting
• Age: 5 to 40 years
• Phase 2

Rett Syndrome (RTT) is a rare neurodevelopmental disorder caused by an MECP2 gene mutation on the X chromosome, primarily affecting females.

Trial name

MirtaRett (NCT07430046)

Testing

mirtazapine

Where

4 sites in Italy

Volunteers

54 people

Sponsor

University of Trieste